MgShell proposes an innovative game changer for the treatment of exudative maculopathy, an intraocular device fully biodegradable intraocular device capable of replicating current clinical practice by drastically reducing the number of intravitreal injections intravitreal injections and thus all the associated discomforts. The device represents the only technological solution capable of replicating current clinical practice by releasing the same therapeutic doses of drug used today in the clinic at specific times, in an autonomously and without surgical procedures. The product is the result of a win-win-win philosophy: MgShell increases patient adherence to treatment by reducing the risk of irreversible blindness, reduces the costs associated with the treatment of each patients borne by healthcare systems and creates business opportunities for pharmaceutical companies.